[Metalloproteinases: therapeutic target in atherosclerosis].
Matrix metalloproteinases are a family of enzymes which collectively can cleave all components of the extracellular matrix. In physiological situations, the expression of matrix metalloproteinases is very low. The increase of their expression leads to several diseases as atherosclerosis, restenosis, rheumatoid arthritis and cancers. In atherosclerosis, metalloproteinases are implicated in the rupture of the atheromatous plaque and contribute to acute vascular accident. Consequently, several studies hypothesized that the inhibition of matrix metalloproteinases activity could reduce the volume of the atheromatous plaque and prevent its destabilisation and therefore could be useful in the treatment of atherosclerosis. However, clinical results have so far been inconclusive because matrix metalloproteinases inhibitors are not very specific. The development of selective inhibitors and gene transfer approaches may better suit the treatment of atherosclerosis.
Jguirim-Souissi
Imen
I
Unité de recherche sur les facteurs génétiques et biologiques de l'athémrosclérose UR/09-12/Laboratoire de Biochimie, Faculté de Médecine, Monastir, Tunisie.
Jelassi
Awatef
A
Najah
Mohamed
M
Rouis
Mustapha
M
Slimane
Mohamed Naceur
MN
D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy* / Q000201:enzymology*; D006801:Humans; D045726:Metalloproteases / Q000037:antagonists & inhibitors* / Q000502:physiology
D045726:Metalloproteases